BGPartner advises series C financing

BGPartner advises lead investors HBM Healthcare Investments Ltd. and Novo Holdings A/S on CHF 100 mio financing round of Numab Therapeutics Ltd.

HBM Healthcare Investments Ltd and Novo Holdings A/S as co-lead-investors, together with other investors including Forbion and Black Rock, successfully closed an investment in Numab Therapeutics Ltd’s series C financing round, raising a total amount of CHF 100 million.

Numab Therapeutics Ltd is a clinical stage biopharmaceutical company developing next-generation multi-specific antibody-based immunotherapies for cancer and inflammation. The proceeds will support acceleration and expansion of the clinical development of Numab’s lead program NM21-1480 into multiple cancer indications, and the advancement of the company’s pipeline of multi-specific antibodies in oncology and inflammation, into clinical trials.

BGPartner assisted HBM Healthcare Investments Ltd and Novo Holdings A/S in the negotiations and advised them on all Swiss legal matters with regard to the series c financing round. The team was led by Oliver Gnehm (Partner) and further consisted of Olivier Bula (Partner), Victoria Marty (Associate), Thomas Gysin (Associate) and Fabiola Anthamatten (Associate).

BGPartner has been repeatedly awarded as top law firm in the area of "Private Equity and Venture Capital". More information can be found here.